Danicopan: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies -43% 1 201 Improvement, Studies, Patients Relative Risk Mortality -43% 1 201 Ventilation -17% 1 184 Hospitalization -19% 1 195 RCTs -43% 1 201 Late -43% 1 201 Danicopan for COVID-19 c19early.org December 2025 Favorsdanicopan Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ACTIV-5 BET-C Beigel (DB RCT) -43% 1.43 [0.76-2.68] death 19/98 14/103 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 Late treatment -43% 1.43 [0.76-2.68] 19/98 14/103 43% higher risk All studies -43% 1.43 [0.76-2.68] 19/98 14/103 43% higher risk 1 danicopan COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 Effect extraction pre-specified(most serious outcome) Favors danicopan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ACTIV-5 BET-C Beigel (DB RCT) -43% 1.43 [0.76-2.68] 19/98 14/103 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 Late treatment -43% 1.43 [0.76-2.68] 19/98 14/103 43% higher risk All studies -43% 1.43 [0.76-2.68] 19/98 14/103 43% higher risk 1 danicopan COVID-19 mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 Favors danicopan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ACTIV-5 BET-C Beigel (DB RCT) -17% 1.17 [0.61-2.25] 16/91 14/93 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.66 Late treatment -17% 1.17 [0.61-2.25] 16/91 14/93 17% higher risk All studies -17% 1.17 [0.61-2.25] 16/91 14/93 17% higher risk 1 danicopan COVID-19 mechanical ventilation result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.66 Favors danicopan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ACTIV-5 BET-C Beigel (DB RCT) -19% 1.19 [0.80-1.76] hosp. time 96 (n) 99 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.4 Late treatment -19% 1.19 [0.80-1.76] 96 (n) 99 (n) 19% higher risk All studies -19% 1.19 [0.80-1.76] 96 (n) 99 (n) 19% higher risk 1 danicopan COVID-19 hospitalization result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.4 Favors danicopan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ACTIV-5 BET-C Beigel (DB RCT) -54% 1.54 [1.09-2.17] no recov. 96 (n) 99 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.015 Late treatment -54% 1.54 [1.09-2.17] 96 (n) 99 (n) 54% higher risk All studies -54% 1.54 [1.09-2.17] 96 (n) 99 (n) 54% higher risk 1 danicopan COVID-19 recovery result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.015 Favors danicopan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ACTIV-5 BET-C Beigel (DB RCT) -43% 1.43 [0.76-2.68] death 19/98 14/103 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 Late treatment -43% 1.43 [0.76-2.68] 19/98 14/103 43% higher risk All studies -43% 1.43 [0.76-2.68] 19/98 14/103 43% higher risk 1 danicopan COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 Effect extraction pre-specified(most serious outcome) Favors danicopan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ACTIV-5 BET-C Beigel (DB RCT) -43% 1.43 [0.76-2.68] 19/98 14/103 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 Late treatment -43% 1.43 [0.76-2.68] 19/98 14/103 43% higher risk All studies -43% 1.43 [0.76-2.68] 19/98 14/103 43% higher risk 1 danicopan COVID-19 RCT mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 Favors danicopan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ACTIV-5 BET-C Beigel (DB RCT) -43% 1.43 [0.76-2.68] death 19/98 14/103 Improvement, RR [CI] Treatment Control ACTIV-5 BET-C Beigel (DB RCT) -17% 1.17 [0.61-2.25] ventilation 16/91 14/93 ACTIV-5 BET-C Beigel (DB RCT) -54% 1.54 [1.09-2.17] no recov. 96 (n) 99 (n) ACTIV-5 BET-C Beigel (DB RCT) -37% 1.37 [0.99-1.90] no improv. 96 (n) 99 (n) ACTIV-5 BET-C Beigel (DB RCT) -30% 1.30 [0.94-1.79] no improv. 96 (n) 99 (n) ACTIV-5 BET-C Beigel (DB RCT) -19% 1.19 [0.80-1.76] hosp. time 96 (n) 99 (n) Danicopan COVID-19 outcomes c19early.org December 2025 Favors danicopan Favors control